{"text": "$ABBV [15s. delayed] filed SEC form 4: Chairman of the Board and CEO GONZALEZ RICHARD A: \nGranted 167,906 of Common Stock at average price $0 on 2021-02-18, increased holding by 59% to 454,306 shares  https://t.co/GxiZDqzuYA", "created_at": "2021-02-22T23:19:15.000Z", "id": "1363991775069765639", "author_id": "1069693680066420736"}
{"text": "$ABBV: Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ\u2122) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients", "created_at": "2021-02-22T13:46:13.000Z", "id": "1363847566413074433", "author_id": "1295909072915451904"}
{"text": "$ABBV \ud83d\udcdc SEC Form 4: A. Robert Michael was granted 31,613 units of Common Stock, increasing ownership by 156% to 51,883 units\n\nhttps://t.co/Y67SotlA8K\n\n#majorpharmaceuticals #healthcare", "created_at": "2021-02-22T23:25:49.000Z", "id": "1363993429219270658", "author_id": "1325115160353103872"}
